York biotech business, OptiBiotix, has launched a new product aimed at improving gut health.
The listed company has launched WellBiome – an evolution of its weight loss ingredient SlimBiome – to promote the diversity of the gut microbiome.
The move sees the company extend its product value proposition into the health and wellness market at a time when more people are prioritising their health.
“The launch of WellBiome is another step in OptiBiotix’s strategy of developing functional ingredients which modify the human microbiome to improve health,” said Stephen O’Hara, CEO of OptiBiotix Health.
“Consumer understanding and interest in the microbiome is growing rapidly, particularly in the US, and this is creating a market opportunity that is large and expanding.
“The development of functional ingredients like WellBiome, backed by science and clinical studies and protected by a broad IP portfolio, allows OptiBiotix and its partners to access this large and growing health and wellbeing trend.”
Dr Fred Narbel, Managing Director of OptiBiotix’s prebiotics division, added: “The addition of WellBiome to OptiBiotix’s portfolio allows the company to extend its reach beyond the weight management category increasing the scale of the commercial opportunity.”